Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. CRWV

Go back to Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
(NYSE: NSRX) Delayed: 2.88 -0.29 (9.15%)
Previous Close $3.17    52 Week High $ 
Open $3.21    52 Week Low $ 
Day High $3.24    P/E N/A 
Day Low $2.88    EPS $ 
Volume 42,183